Feigal Aids Small To Mid-Sized Device, Biologic Firms In Consultant Capacity
This article was originally published in The Gray Sheet
Executive Summary
Former CDRH Director David Feigal, MD, will commit at least three days a week to NDA Partners, a product development consulting firm, where he will help build a client base for medical devices and biologics
You may also be interested in...
CDRH Leadership Changes May Be Imminent; NCI’s Ellen Feigal To Leave Institute
FDA is vetting a list of more than 20 candidates for a CDRH clinical deputy spot - a position that may grow in stature with the potential departure of Director David Feigal
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.